An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Amikacin (Primary)
- Indications Mycobacterium avium complex infections; Respiratory tract infections
- Focus Adverse reactions
- Sponsors Insmed
- 30 Aug 2017 This trial has been completed in Spain.
- 17 Aug 2017 This trial has been completed in Sweden.
- 15 Dec 2015 New trial record